—A large international team of experts examined relapse activity and disability progression among pregnant and nonpregnant women of reproductive age with moderate-to-severe multiple sclerosis (MS).

In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by ...

A study of more than 22,000 people with multiple sclerosis (MS) has for the first time identified a genetic variant associated with faster progression of the disease, an accumulation of disability ...

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

BOSTON – A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

Pregnancy post-glioma diagnosis is associated with worse progression-free survival, but no deterioration occurs during pregnancy itself. Patients who had children after glioma diagnosis showed a 2.45 ...